On April 20th FDA's orthopedic device panel overwhelmingly voted for Cartiva, a first-in class toe implant to treat osteoarthritis. Immediately following the meeting The Gray Sheet spoke to Cartiva CEO Tim Patrick about the panels votes.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
